AN ACTIVATED MURINE B-CELL LYMPHOMA LINE (A-20) PRODUCES A FACTOR-LIKE ACTIVITY WHICH IS FUNCTIONALLY RELATED TO HUMAN NATURAL-KILLER-CELL STIMULATORY FACTOR

被引:24
|
作者
MENGEL, J
DARE, L
DARE, GM
DELGADO, M
NOMIZO, A
SILVA, JS
CAMPOSNETO, A
机构
[1] Department of Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Ribeirão Preto
关键词
D O I
10.1002/eji.1830221222
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the present article we show that supernatants derived from lipopolysaccharide (LPS) or phorbol 12-myristate 13-acetate (PMA)-stimulated A-20 B cell lymphoma are able to induce polyclonal immunoglobulin (Ig) secretion by normal B cells in a T cell-dependent manner. This activity could be blocked by neutralizing monoclonal antibodies against interferon-gamma, but not by monoclonal antibodies against interleukin (IL)-2, IL-4, IL-5, IL-6, IL-10 and granulocyte macrophage colony-stimulating factor (GM-CSF) or even a polyclonal antibody against tumor necrosis factor (TNF)-alpha. Furthermore, A-20 supernatants induced the production of measurable amounts of interferon-gamma by normal murine spleen cells and activates natural killer (NK) cells. Fractionation of factor-rich supernatants on a Sephacryl S-200 column revealed that the factor activity is located in the fractions corresponding to a molecular mass of 160-150 kDa and 80-70 kDa. The biological activities found in the A-20 supernatant are very similar to the ones described for the recently cloned human IL-12/NK cell stimulatory factor. These results suggest the existence of a murine analogous factor for the human IL-12 produced by A-20 B cell lymphoma.
引用
收藏
页码:3173 / 3178
页数:6
相关论文
共 50 条
  • [21] TISSUE FACTOR-LIKE ACTIVITY OF THE HUMAN MONOCYTIC TUMOR-CELL LINE-U937
    HUDIG, D
    BAJAJ, SP
    THROMBOSIS RESEARCH, 1982, 27 (03) : 321 - 332
  • [22] BASIC FIBROBLAST GROWTH FACTOR-LIKE ACTIVITY AND RECEPTORS ARE EXPRESSED IN A HUMAN GLIOMA CELL-LINE
    MORRISON, RS
    GROSS, JL
    HERBLIN, WF
    REILLY, TM
    LASALA, PA
    ALTERMAN, RL
    MOSKAL, JR
    KORNBLITH, PL
    DEXTER, DL
    CANCER RESEARCH, 1990, 50 (08) : 2524 - 2529
  • [24] Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha
    Katrinakis, G
    Kyriakou, D
    Papadaki, H
    Kalokyri, I
    Markidou, F
    Eliopoulos, GD
    ACTA HAEMATOLOGICA, 1996, 96 (01) : 16 - 23
  • [25] DEFECT IN PRODUCTION OF B-CELL DIFFERENTIATION FACTOR-LIKE ACTIVITY BY MONONUCLEAR-CELLS FROM A BOY WITH HYPOGAMMAGLOBULINEMIA
    MATHESON, DS
    GREEN, BJ
    JOURNAL OF IMMUNOLOGY, 1987, 138 (08): : 2469 - 2472
  • [26] EXPRESSION OF SURFACE LYMPHOTOXIN AND TUMOR-NECROSIS-FACTOR ON ACTIVATED T-CELL, B-CELL, AND NATURAL-KILLER-CELLS
    WARE, CF
    CROWE, PD
    GRAYSON, MH
    ANDROLEWICZ, MJ
    BROWNING, JL
    JOURNAL OF IMMUNOLOGY, 1992, 149 (12): : 3881 - 3888
  • [27] Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
    Davis, RE
    Brown, KD
    Siebenlist, U
    Staudt, LM
    JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (12): : 1861 - 1874
  • [28] A LOW-MOLECULAR-WEIGHT NATURAL-KILLER CELL-DERIVED FACTOR CAN AUGMENT HUMAN B-CELL PROLIFERATION
    KATZ, P
    AMBRUS, JA
    WHALEN, G
    EVANS, M
    MCFARLAND, P
    CLINICAL RESEARCH, 1990, 38 (02): : A548 - A548
  • [29] PRODUCTION OF B-CELL STIMULATORY FACTOR-II INTERLEUKIN-6 ACTIVITY BY HUMAN-ENDOTHELIAL CELLS
    NORIOKA, K
    HARA, M
    HARIGAI, M
    KITANI, A
    HIROSE, T
    SUZUKI, K
    KAWAKAMI, M
    TABATA, H
    KAWAGOE, M
    NAKAMURA, H
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 153 (03) : 1045 - 1050
  • [30] Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression
    Azoulay, Tehila
    Slouzky, Ilana
    Karmona, Michal
    Filatov, Margarita
    Hayun, Michal
    Ofran, Yishai
    Sarig, Galit
    Ringelstein-Harlev, Shimrit
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (03) : 707 - 718